A Multicenter, Open-label, Randomized, 3-arm, Phase II Profiling Trial of Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Treatment naive Patients
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2016
At a glance
- Drugs Alisporivir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Debiopharm; Novartis; Novartis Pharma
- 24 Mar 2016 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 16 Sep 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
- 18 Jun 2014 Planned End Date changed from 1 Feb 2015 to 1 Mar 2015, as per ClinicalTrials.gov record.